ALDX

Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for immune-mediated diseases. Headquartered in Lexington, Massachusetts, the company concentrates on discovering therapies that target reactive aldehyde species (RASP), which are elevated in ocular and systemic diseases. Aldeyra's lead product candidate, reproxalap, is a RASP inhibitor being developed for dry eye disease and allergic conjunctivitis, having completed multiple Phase 3 clinical trials. The company's pipeline also includes ADX-629, an orally administered RASP modulator in development for systemic immune-mediated conditions, and ADX-2191, a dihydrofolate reductase inhibitor being studied for proliferative vitreoretinopathy. In 2024, Aldeyra received a Complete Response Letter from the FDA regarding reproxalap's New Drug Application for dry eye disease, prompting additional clinical development work. The company operates with approximately 50 employees and maintains strategic manufacturing partnerships to support its clinical programs. Aldeyra collaborates with academic institutions and research organizations to advance its understanding of aldehyde trap mechanisms and their therapeutic applications. The company funds operations primarily through equity financings and strategic partnerships, with no products currently generating revenue as all candidates remain in clinical development stages.